The secretin receptor is a prototypic member of family B G protein-coupled receptors (GPCRs) that includes multiple potentially important drug targets (1). Understanding the molecular basis of ligand binding and activation of these receptors will facilitate the rational design of receptoractive drugs. However, due to limited information regarding the structures of the intact receptors, the molecular basis of ligand binding and activation of these receptors is not yet clear.
The secretin receptor is a prototypic member of family B G protein-coupled receptors (GPCRs) that includes multiple potentially important drug targets (1) . Understanding the molecular basis of ligand binding and activation of these receptors will facilitate the rational design of receptoractive drugs. However, due to limited information regarding the structures of the intact receptors, the molecular basis of ligand binding and activation of these receptors is not yet clear.
Since the resolution of the threedimensional structure of the β2 adrenergic receptor (2) , a growing number of such structures have been solved for members of the family A GPCRs (3) (4) (5) (6) (7) (8) . While family B GPCRs share the heptahelical topology and G protein coupling with family A GPCRs, they do not have the typical signature sequences of that family and have their own typical motifs. These include a relatively long, disulfide-bonded amino-terminal domain, which functions as the predominant site of ligand docking, with determinants for interaction with the peptide carboxyl terminus. To date, NMR and crystal structures have been described for the isolated ligand-bound amino-terminal domains of several family members including receptors for corticotropinreleasing factor (9-11), glucose-dependent insulinotropic polypeptide (GIP) (12) , glucagon-like peptide 1 (GLP1) (13, 14) , pituitary adenylate cyclase-activating peptide (PACAP) (15) , parathyroid hormone (PTH 1 ) (16) , and calcitonin gene-related peptide (17, 18) . Although these suggest a shared general mode of ligand binding, there are inconsistencies in the specific docking of the ligands within these structures (19) , suggesting some variation in binding mechanisms among family members. In addition, these structures do not provide any insights into the mode of docking of the flexible amino-terminal regions of the ligands that are critical for their biological activity.
Currently, no three dimensional structures are available for the intact receptors in family B GPCRs and even the orientation of amino-terminal and core helical bundle domains is not yet clear. The most useful insights into the ligand binding to the intact receptor come from photoaffinity labeling studies of the secretin receptor. Using this approach, we previously demonstrated that secretin residues 6, 12, 13, 16, 18, 21, 22, 23 and 26 are spatially approximated with the receptor amino terminus (20, 21) . Photolabile residues in positions 1 and 5 labeled the top of the sixth transmembrane segment and third extracellular loop of the receptor, respectively (22, 23) . These studies support the two-domain tethering mechanism that has been proposed for activation of family B GPCRs (23) (24) (25) .
In this work, we have developed, characterized, and applied five additional secretin probes, incorporating a photolabile residue into positions spread throughout the secretin peptide, including residues 2, 15, 20, 24 and 25. These were used to gain additional insights into spatial approximations that might help to refine our insights into structure and mode of docking. These probes were all full agonists that bound to the secretin receptor specifically and that covalently labeled distinct single residues within the receptor. The position 15, 20 and 25 probes continued to label receptor residues within the distal amino terminus, while the position 24 probe labeled a residue within the carboxylterminal region of the amino-terminal domain adjacent to the first transmembrane segment (TM1). Of particular interest, the amino-terminal position 2 probe labeled a residue within the first extracellular loop (ECL1), a region that has not previously been labeled. These five pairs of experimentally-derived constraints were used to refine our working molecular model of the ligand-bound secretin receptor that had previously been proposed based on eleven pairs of spatial approximation constraints (21) . These findings provide new insights into the relative orientation of the two major receptor domains and how ligand binding might contribute to receptor activation.
EXPERIMENTAL PROCEDURES
Materials-Rat secretin, [Tyr 10 rat secretin and endoglycosidase F were prepared in our laboratory (26, 27) . Endoproteinase Lys-C (Lys-C) was from Roche Applied Science (Indianapolis, IN). Cyanogen bromide (CNBr), solid-phase oxidant, N-chlorobenzenesulfonamide (iodobead) and m-maleimidobenzoyl-Nhydroxysulfosuccinimide ester (sulfo-MBS) were purchased from Pierce Chemical Company (Rockford, IL). 3-isobutyl-1-methylxanthine and N-(2-aminoethyl-1)-3-aminopropyl glass beads were from Sigma (St. Louis, MO). Fetal Clone II was from Hyclone Laboratories (Logan, UT) and tissue culture medium was from Gibco (Grand Island, NY). All other reagents were of analytical grade. . Each probe incorporated a tyrosine residue in position 10 to replace a leucine as a site for radioiodination that has previously been well tolerated (29, 30) . All these peptides were synthesized using manual solid-phase synthesis techniques with Pal resin (Advanced ChemTech, Louisville, KY) and Fmoc-protected amino acids, as described previously (31) . After completion of the synthesis, each peptide was cleaved from the resin using a solution of 6.25% (wt/vol) phenol, 2% (vol/vol) triisopropylsilane, 4% (vol/vol) thioanisole, 4% (vol/vol) distilled water, and 83% (vol/vol) trifluoroacetic acid and was purified by reversed-phase HPLC, as we described previously (31) .
Peptides-The
The photolabile secretin probe, [N 3 -Phe 2 ,Tyr 10 ]rat secretin (N 3 -Phe 2 probe), was designed to replace Ser 2 , with a N 3 -Phe. To minimize the negative impact on binding affinity and biological activity of making modifications within the structurally critical amino-terminal region of the peptide, N 3 -Phe was used instead of a Bpa to take advantage of its smaller size. For this, an Fmoc-(p-Boc-amino)phenylalanine was incorporated into position 2 to replace serine during synthesis. The Fmoc protection of the α-amino group was initially removed by treatment with piperidine. Then, the peptide was cleaved from the resin and all other side chain-protecting groups were removed using the trifluoroacetic acid solution described above. The p-amino group of the (pamino)phenylalanine was subsequently converted to an azido group (N 3 -) using the procedure described previously (32) , and the peptide was purified to homogeneity by reversed-phase HPLC (31) . All the procedures were performed under reduced light to minimize photoactivation of the azido group.
All above probes and the radioligand [Tyr 10 ]rat secretin were radioiodinated oxidatively using 1 mCi Na 125 I (PerkinElmer, Waltham, MA) and exposure to the solid-phase oxidant, iodobead for 15 s, and were purified using reversed-phase HPLC to yield specific radioactivities of 2,000 Ci/mmol (27) .
Receptor Resources-CHO cell lines stably expressing the wild type (CHOSecR) and HA-tagged rat secretin receptors that had been previously established (CHO-HA37-SecR and CHO-HA79-SecR) (27, 33) were used as receptor sources for the current study. These cells were cultured in Ham's F-12 medium supplemented with 5% Fetal Clone II in a humidified atmosphere containing 5% CO 2 at 37 °C and they were passaged approximately twice per week.
It was necessary to develop two new secretin receptor mutants to eliminate sites of CNBr cleavage for the current work. These were secretin receptor constructs M123L and M197L in which residues Met 123 and Met 197 were each replaced by a leucine. They were generated using the QuikChange Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA), with the products verified by direct DNA sequencing. They were expressed transiently in COS-1 cells (American Type Culture Collection, Manassas, VA) grown in Dulbecco's modified Eagle's medium supplied with 5% Fetal Clone II after transfection using a modification of the diethylaminoethyldextran method (34) .
Receptor-expressing CHO and COS-1 cells were harvested mechanically after being grown to confluence. Plasma membranes were prepared from these cells using discontinuous sucrose gradient centrifugation (26) 10 ]rat secretin-27 (5 pM, approximately 20,000 cpm), in the presence of increasing concentrations (ranging from 0 to 1 µM) of secretin or the photolabile secretin probes in KRH medium containing 0.01% STI, 1 mM PMSF and 0.2% bovine serum albumin. Bound and free radioligand were separated using a Skatron cell harvester with glassfiber filter mats that had been soaked in 0.3% polybrene, and bound radioactivity was quantified in a γ-spectrometer. Nonspecific binding was determined in the presence of 1 µM secretin and represented less than 15% of total radioligand binding. The same assay was also utilized to characterize the binding activity of the M123L and M197L secretin receptor mutants expressed in COS-1 cells. Binding curves were analyzed and plotted using the non-linear regression analysis program in the Prism software suite v3.02 (GraphPad Software, San Diego, CA). Binding kinetics were determined by analysis with the LIGAND program of Munson and Rodbard (35) . Data are reported as the means ± S.E.M. of duplicate determinations from a minimum of three independent experiments. Biological Activity Assay-To determine the biological activity of each of the photolabile secretin probes, their abilities to stimulate cAMP responses in receptorbearing CHO-SecR cells were examined. In brief, approximately 8,000 CHO-SecR cells per well were grown in 96-well plates for two days. After cells were washed with PBS, they were stimulated for 30 min at 37 °C with increasing concentrations of secretin or each of the photolabile secretin probes (ranging from 0 to 1 μM) in KRH medium containing 0.01% STI, 0.2% bovine serum albumin, 0.1% bacitracin, and 1 mM 3-isobutyl-1-methylxanthine. After incubation, supernatants were removed by aspiration and cells were lysed with 6% ice-cold perchloric acid. The cell lysates were adjusted to pH 6 with 30% KHCO 3 and were introduced into an assay of cAMP levels using a LANCE™ cAMP-384 kit from PerkinElmer (Boston, MA). The assay was performed as per manufacturer's instructions and repeated in at least three independent experiments. This assay was also used for characterizing the M123L and M197L secretin receptor mutants transiently expressed in COS-1 cells.
Photoaffinity LabelingMembranes (approximately 50 µg) from CHO-SecR cells or COS-1 cells expressing secretin receptor mutants were incubated in the dark for 1 h at room temperature with each of the radioiodinated photolabile secretin probes (approximately 0.1 nM) in KRH medium containing 0.01% STI and 1 mM PMSF in the presence of increasing amounts of competing secretin (ranging from 0 to 1 µM). The reactions were then exposed to photolysis for 30 min at 4 °C using a Rayonet photochemical reactor (Southern New England Ultraviolet Co., Bradford, CT) equipped with 3500-Å lamps. After being washed with ice-cold KRH medium, membranes were solubilized in SDS sample buffer and separated on 10% SDS-polyacrylamide gels. Bands of interest were visualized by autoradiography and densitometric analysis was performed by the NIH ImageJ software. The apparent molecular weights of the radioactive bands were determined by interpolation on a plot of the mobility of the appropriate ProSieve protein Markers (Cambrex, Rockland, ME) versus the log values of their apparent masses.
Peptide Mapping-This required larger scale preparation of affinity labeled receptors. Approximately 200 µg cell membranes were incubated with each of the radioiodinated photolabile secretin probes (~0.5 nM) in the absence of competing secretin. After electrophoresis, radioactive bands of interest were excised from gels, eluted in water, lyophilized and ethanol precipitated, as described previously (33) . For selected experiments, receptor samples were deglycosylated by treatment with endoglycosidase F (26) . Cleavage of the labeled wild-type or mutant secretin receptors with CNBr and Lys-C was performed using protocols that we described previously (33) , with the products of cleavage analyzed on 10% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA) using MES running buffer system under reducing conditions. The radiolabeled bands were visualized by autoradiography, with their apparent molecular weights determined by interpolation on a plot of the mobilities of the appropriate Multimark multicolored standards (Invitrogen) versus the log values of their apparent masses.
Radiochemical Sequencing-To identify the specific receptor residues labeled with each of the photolabile secretin probes, manual Edman degradation radiochemical sequencing was performed (36) . It should be noted that for the position 2 probe, after photoaffinity labeling, but prior to CNBr cleavage, the labeled membranes were treated by acetic anhydride (23) . This was performed to block the amino terminus of this probe by acetylation and to prevent it from being cleaved during sequencing. , and Cys 24 /Cys 44 residues, respectively, to mmaleimidobenzoyl-N-succinimide-activated N-(2-aminoethyl-1)-3-aminopropyl glass beads. Immobilized fragments were subjected to manual Edman degradation sequencing as described previously (36) . Radioactivity eluted in each cycle was quantified using a γ-spectrometer.
Molecular Modeling-All molecular modeling was conducted using a stochastic global energy optimization procedure in Internal Coordinate Mechanics (ICM) (37) with the ICM-Pro package version 3.7 (MolSoft LLC, San Diego, CA). This procedure consisted of three iterative steps: (a) random conformational change of a dihedral angle according to the biasedprobability Monte Carlo method (38) ; (b) local minimization of all free dihedral angles; and (c) acceptance or rejection of the new conformation based on the Metropolis criterion at the simulation temperature, usually at 600 K (39) . The initial model of the amino-terminal domain of the secretin receptor was generated using the X-ray structure of the amino terminus of the GIP receptor complexed with the GIP peptide (PDB code: 2QKH (12) to Phe 349 ; and 12 FRET distance constraints between the peptide and the transmembrane domain, as previously described (22) . All the resultant models were clustered, ranked by their ICM energetics and their health as established by PROCHECK and WHAT_CHECK evaluations (41, 42) . The three best models from 200 independent runs were selected.
RESULTS

Photolabile
Probe Characterization-Each of the photolabile secretin probes was synthesized, purified to homogeneity, with its identity verified by mass spectrometry. Probes were functionally characterized, to determine their abilities to bind to the wild-type secretin receptor and to stimulate intracellular cAMP accumulation in secretin receptor-bearing CHO-SecR cells. Photoaffinity Labeling of the Secretin Receptor-Each of the position 2, 15, 20, 24 and 25 probes was used in photoaffinity labeling experiments with CHO-SecR cell membranes in the absence and presence of competing secretin to explore their abilities to covalently label the secretin receptor (Fig. 2) . Figure 3 shows that each probe labeled this receptor specifically and saturably, with labeling by each probe inhibited by secretin in a concentration-dependent manner (IC 50 values in nM for position 2, 15, 20, 24 and 25 probes: 4.5 ± 1.2, 4.9 ± 1.3, 9.9 ± 2.1, 51 ± 12, and 101 ± 20, respectively). The labeled secretin receptor migrated at approximate M r = 70,000 and shifted to approximate M r = 42,000 after deglycosylation with endoglycosidase F. No receptor bands were detected in affinitylabeled non-receptor-bearing CHO cell membranes. The receptor bands migrated identically to those labeled with other secretin probes that we previously reported (20) (21) (22) .
Site Identification-The secretin receptor contains nine methionine residues distributed throughout the molecule, whereby CNBr cleavage should yield ten fragments with molecular masses ranging from 1 to 11 kDa, of which three contain sites of glycosylation. CNBr cleavage has been proven very useful in identification of regions and even sites of labeling for secretin probes (20) (21) (22) . Here again, it was used to provide the first indication of the region of labeling with each probe. As shown in Figure 3 , CNBr cleavage of the secretin receptor labeled with the position 2 probe yielded a single radioactive band migrating at approximate M r = 4,500 that did not further shift after deglycosylation by endoglycosidase F. Given its nonglycosylated nature and the mass of the attached N 3 (21, 43) , and this was confirmed by immunoprecipitation of HAtagged fragments from CNBr cleavage of a well-characterized receptor mutant (HA79-SecR) incorporating an HA epitope within this fragment (data not shown).
Two secretin receptor mutants, M123L and M197L, were used to identify which of the two above-mentioned candidate fragments contained the site of labeling by the position 2 probe. Both receptor mutants bound secretin (K i values in nM: wild-type, 1.9 ± 0.5; M123L, 3.5 ± 0.9; M197L, 3.1 ± 0.5) and signaled similarly to the wild-type receptor (EC 50 values in pM: wild-type, 21 ± 8; M123L, 32 ± 11; M197L, 50 ± 14). They were also specifically and saturably labeled with the position 2 probe (data not shown). CNBr cleavage of the labeled M123L receptor mutant yielded a labeled fragment that migrated at approximate M r = 4,500 on a 10% NuPAGE gel, similar to that coming from the wildtype receptor. In contrast, CNBr cleavage of the labeled M197L receptor mutant yielded a much larger fragment migrating at approximate M r = 9,000, representing the His 158 -Met 205 fragment spanning TM2 to TM3 of the receptor (Fig. 4) . This identified the receptor fragment Ile 198 -Met 205 spanning ECL1 and TM3 as the region of labeling by the position 2 probe. Endoproteinase Lys-C, which specifically cleaves at the carboxyl terminus of lysine residues, was used to further refine the receptor region labeled by the position 15, 20 and 25 probes. As shown in Figure 5 , Lys-C cleavage of the first CNBr fragment (Ala 1 -Met 51 ) labeled by each of these probes yielded a fragment migrating at approximate M r = 6,000 that did not shift after delycosylation. This identified the nonglycosylated Ala 1 -Lys 30 fragment at the distal amino terminus of the secretin receptor as the region of labeling by each of the position 15, 20 and 25 probes.
A previously-characterized V16M mutant secretin receptor (44) was used to further refine the region of labeling by the position 15, 20 and 25 probes. As shown in Figure 6 , CNBr cleavage of the V16M mutant receptor labeled by the position 20 probe yielded a non-glycosylated band migrating at approximate M r = 6,000, representing the labeling of the aminoterminal Ala 1 of labeling by the position 24 probe. As shown in Figure 7 , Lys-C cleavage of the labeled wild-type secretin receptor yielded a band migrating at approximate M r = 30,000 and shifting to approximate M r = 8,000 after deglycosylation, consistent with labeling the Asn 78 -Lys 119 fragment. Lys-C cleavage of the labeled R96K receptor resulted in a band migrating at approximate M r = 12,500 and shifting to approximate M r = 6,500 after deglycosylation, consistent with labeling the carboxyl-terminal Pro 97 -Lys 119 segment (21, 43) . Figure 7 also shows that CNBr cleavage of the labeled N106M receptor yielded a band migrating at approximate M r = 23,000 and shifting to approximate M r = 7,000, distinct from the pattern of cleavage of the wild-type secretin receptor (M r = 31,000 shifting to M r = 9,000 after deglycosylation), indicating that the Leu 74 -Met 106 fragment was the region of labeling (21) . Taken together, the site of labeling with the position 24 probe was localized to the region between Pro 97 and Asn 106 of the secretin receptor.
The specific receptor residues labeled with each of the position 2, 15, 20, 24 and 25 probes were identified by manual Edman degradation radiochemical sequencing of relevant receptor fragments that had been purified to radioactive homogeneity. As shown in Figure 8 Molecular Model of the Intact Secretin Receptor-The X-ray crystal structure of the amino terminus of the GIP receptor complexed with the GIP peptide provided a starting point for modeling the amino-terminal domain of the secretin receptor. As noted in our previous work (21) , a direct superposition of the secretin receptor/secretin complex to the GIP receptor/GIP complex did not satisfy the experimental constraints imposed by data from photoaffinity labeling experiments with a series of full agonist peptide ligands. Therefore, the secretin peptide was docked and globally optimized with the secretin receptor in the presence of these experimental spatial approximation constraints. The recently released X-ray crystal structure of CXCR4 (8) provided a different template for core helical bundle modeling from the β2 adrenergic receptor template we had used previously (2) . Each of the 25 conformations of amino-terminal secretin receptor domain/secretin peptide complexes was docked to 200 transmembrane domain models in the presence of all experimental constraints, followed by all-atom refinements generating the final models. Three of the best models were selected as being representative. Table 1 shows the distances between positions of cross-linked residues in these three models, each of which satisfies all current experimentally-derived constraints. Distances were measured from the C β of the natural amino acid in the position of the Bpa in the peptide ligand (except when it was a glycine) to the noted atom within the labeled receptor residue. Given the size of the photolabile Bpa moiety, an approximate 8-10 Å distance is typical. Figure 9 shows the spatial approximation between the photolabile residues within the secretin probe and the receptor residues labeled in one of the best molecular models of the secretin-bound secretin receptor. Figure 10 shows how similar all three of the best molecular models were to each other. In this, the backbones of the transmembrane segments were superimposed and the amino-terminal domains and docked peptides were shown to vary only minimally.
DISCUSSION
Understanding the molecular basis of the docking of a ligand to a receptor requires insights into the structures of each of these molecules. The docking of the natural peptide secretin ligand to its family B GPCR is challenged by the flexibility of the ligand and by lack of insight into the structure of the intact receptor. While considerable progress has been achieved with the solution of high resolution NMR and crystal structures for the amino-terminal domains of several members of this receptor family (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , much less is understood about the core helical bundle domains of these receptors and virtually nothing is known about the relative orientation of these two major domains.
In the current work, we have developed, characterized, and applied five new photolabile probes to establish spatial approximations between residues spread throughout the secretin pharmacophore and residues within the secretin receptor. This brings the total of such spatial approximation constraints to 16 of the 27 residues comprising natural secretin. We previously described the application of 11 such probes, with nine of them found to covalently label the receptor amino-terminal domain (20, 21, 33, (44) (45) (46) (47) , and only probes with sites of covalent attachment in positions five and one (or an amino-terminal extension before the one position) were found to label the receptor core helical bundle domain (22, 23) . Application of those spatial approximation constraints was insufficient to refine a general working model of the intact secretin receptor (21) . In the current report, the new spatial approximation constraints have provided substantial refinement of our understanding of the structure of the intact secretin receptor and have provided more meaningful insights into the docking of the amino-terminal region of secretin, known to be critical for its biological activity.
It is important to draw attention to the N 3 -Phe 2 probe used in this work. The amino-terminal region of secretin is critically important for the biological activity of this hormone (23) , as it is for other natural ligands of family B GPCRs (48) (49) (50) . When modifying secretin to allow incorporation of a photolabile moiety for covalent labeling of the receptor, it is challenging to accommodate a residue with optimal photochemical characteristics without disrupting binding and activity. While benzophenone moieties, like the Bpa used in most of the secretin analogue probes we have developed, have ideal characteristics, typically having high efficiency of incorporation and low levels of background labeling, this represents a bulky hydrophobic group that is not readily accommodated.
Indeed, in developing amino-terminal secretin probes, Bpa in position one was poorly accommodated (23), necessitating situating it in the minus one and minus two positions for receptor labeling (23) . Use of N 3 -Phe 2 in the position two probe provided a functional peptide labeled within this key region of the peptide and the opportunity to determine proximity with the receptor.
In this work, four new probes having a photolabile residue in positions 15, 20, 24 and 25 labeled the amino terminus of the secretin receptor, the same receptor region most commonly labeled in previous studies as well. This reflects the major determinants of natural ligand binding within the peptide-binding cleft of the receptor amino terminus. In contrast, the probe with its photolabile residue in position two labeled receptor residue Phe 199 , within the ECL1-TM3 region of this receptor. This region is distinct from the TM6-ECL3 region labeled by the amino-terminal position one and five probes, representing the only other probes that did not label the receptor amino terminus prior to the current study (22, 23) . Spatial approximation of this secretin probe with the ECL1-TM3 region of the receptor is consistent with mutagenesis data for family B GPCRs (28, 34 15 where they might form an important salt bridge, with loss of ligand binding affinity with disruption of that interaction. In fact, we previously mutated receptor residue Arg 15 to an alanine, and found that the ability of natural secretin to bind to and stimulate cAMP at that mutant were reduced more than 12-fold (47) .
The new molecular model being proposed represents a substantial improvement over our previous working model. The CXCR4 receptor structure (8) , as a family A GPCR that binds a natural peptide ligand, seems to provide a more suitable structural template than the β2 adrenergic receptor structure (2) that was previously utilized. Comparison of the structures of these two receptors reveals the following key differences that contributed to the improvement in our current secretin receptor model: (a) TM1 in the CXCR4 receptor is bent toward the rest of the transmembrane helical bundle, bringing the receptor amino-terminal domain closer to the center of the top of the helical bundle; and (b) TM6 and TM7 in the CXCR4 receptor adopt a more open conformation than they do in the β2 adrenergic receptor, and, therefore, more readily accept the insertion of the peptide amino terminus into the transmembrane helical bundle. Indeed, using this template in the current model resulted in new adjacency and possible contact between the docked secretin peptide and receptor residue Trp 264 ; this residue is analogous to Trp 297 in the GLP1 receptor that has been shown to represent an important determinant for peptide binding (55) . Further, in our previous working model (21) , the peptide amino terminus primarily occupied the region at the top of TM1, TM2, and TM7, whereas, using the CXCR4 receptor as template allows the peptide to come into direct contact with TM6 and TM7. Both of these regions are known to be adjacent to the docked secretin peptide, as shown in the photoaffinity labeling of receptor residues Phe 338 and Phe 349 (22, 23) . This new model also suggests that docked secretin will be adjacent to ECL2 and the top of TM5, a prediction should be further explored in future studies.
Additionally, the new photoaffinity labeling data between peptide residue 2 and Phe 199 of the receptor provides an important additional constraint for positioning the peptide amino terminus within the receptor core. Phe 199 is present below the conserved Cys 193 that is known to be disulfide bonded to Cys 263 in ECL2. As a result, the amino terminus of the secretin peptide is more confidently placed between Phe 338 and Phe 349 of TM6-ECL3-TM7, and Phe 199 of TM3-ECL1. In our previous study (21) , there was considerable variation in the relative orientation of the peptide ligand amino terminus to the receptor core transmembrane domain, even among the best scoring models. In contrast, the three best models in this study generated significantly less variation in the juxtapositions of the two domains, as illustrated in Figure 10 . The positioning of Ser 2 within this aromatic cage also provides a possible reason for the loss in affinity and potency of the N 3 -Phe 2 analogue with even this photoactive substitution likely to sterically clash within the binding pocket.
As the quality of the molecular model of secretin-occupied intact secretin receptor is improved, the insights into molecular mechanisms can be refined. The current model helps to provide support for the "two-domain tethering" concept that has been proposed for family B GPCRs (23) (24) (25) .
It also supports the insights that came from the previous fluorescence studies utilizing secretin analogues with fluorescent alexa at the amino terminus, carboxyl terminus, and mid-regions of the peptide (56) . In those studies, the amino terminus of secretin was most exposed to the hydrophilic milieu and most easily quenched using potassium iodide, with the rest of the peptide protected, such as by its insertion into the peptidebinding cleft. With activation, this cleft opened up to provide more mobility an shorter lifetime of the mid-region fluorophores. It is reassuring to see all the existing data, including photoaffinity labeling constraints with 16 probes, 16 FRET distance constraints (40), fluorescence microdomain insights (56) , and all extant structure-activity data fully accommodated with a working molecular model. While this model does not yet provide the resolution necessary for drug development, it clearly provides new detail to yield testable questions for the future. a Measured from the C β of the corresponding peptide residue, except for Gly 25 measured from C α , to the proximal atom of noted receptor residue. (20) . Cleavage of the secretin receptor labeled by the position 24 probe yielded a fragment migrating at approximate M r = 31,000 that shifted to approximate M r = 9,000 after deglycosylation, likely representing the third CNBr fragment between Leu 74 and Met 123 (21, 43) . Data are representative of at least three independent experiments. fragment (21, 43) . CNBr cleavage of the labeled N106M receptor yielded a band migrating at approximate M r = 23,000 and shifting to approximate M r = 7,000, distinct from the pattern of cleavage of the wild-type secretin receptor (approximate M r = 31,000 shifting to approximate M r = 9,000 after deglycosylation), indicating that the fragment Leu 74 -Asn 106 contained the site of labeling (21) . Taken together, the site of labeling with the position 24 probe was within the region between Pro 97 and Asn 106 of the secretin receptor. Three best molecular models of the ligand-bound secretin receptor. Shown is the high degree of structural similarity among the three best molecular models, superimposed by the backbone of their transmembrane domains. Model 1 is colored gold; model 2 is green; model 3 is blue (in each model, the receptor is in lighter shade, while the peptide is darker).
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